

# Cell Line and Membrane Market

<https://marketpublishers.com/r/C69CC3205C1EN.html>

Date: March 2019

Pages: 176

Price: US\$ 2,750.00 (Single User License)

ID: C69CC3205C1EN

## Abstracts

### REPORT SCOPE:

The scope of this report is broad and covers various types of products available in the cell line and membrane market and potential application sectors across various industries. The cell line and membrane market is segmented by cell line product type and membrane type. Revenue forecasts from 2018 to 2023 are given for each product, application and end user with estimated values derived from the total revenue of manufacturers.

The report also includes a discussion of the major players across each region in the cell line and membrane market. Further, it explains the major drivers and regional dynamics of the global cell line and membrane market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors in the cell line and membrane market.

### REPORT INCLUDES:

79 data tables and 60 additional tables

Identification of applications of cell lines in drug development, diagnostics, and molecular biology

Description of advancements in cell lines for cancer-based therapies

Details of CAR-T Cell and immune check point inhibitor therapy

Comparative study of autologous vs allogenic cells manufacturing process

Explanation of increasing adoption of cell line technologies in cell-based assay and surging demand of antibody production as a driving force to the cell line market

Detailed profiles of the major vendors in the global cell line and membrane market, including ATCC, GE Healthcare, Lonza Group Ltd., Sartorius, Thermo Fisher Scientific and Wuxi AppTec

## Contents

### **CHAPTER 1 INTRODUCTION**

Study Goals and Objectives  
Reasons for Doing This Study  
Scope of Report  
Information Sources  
Methodology  
Geographic Breakdown  
Analyst's Credentials  
BCC Custom Research  
Related BCC Research Reports

### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

### **CHAPTER 3 MARKET OVERVIEW**

Introduction  
Market Potential  
Regulatory Framework  
United States  
European Union  
China  
India  
Japan  
Brazil  
Investment Analysis  
Industry Growth Drivers  
Advancement in Technologies Accelerating the Scale-up of Cell Lines  
High Investment in Cell Culture Technology  
Increasing Adoption of Cell Line Technologies in Cell-Based Assays  
Surging Demand for Antibody Production  
High Investments by Pharmaceutical and Biotechnology Companies in Drug Development

### **CHAPTER 4 MARKET BREAKDOWN BY PRODUCT**

Type of Cell Line

*Cell Line and Membrane Market*

Development of Cell Lines and Cell Culture  
Immunotherapy Cell Lines  
Ion Channel Cell Lines  
GPCR Cell Lines  
Cell Signaling Pathway Cell Lines  
Gene Knockout Cell Lines  
Cancer Cell Lines  
Others  
Type of Cell Membrane  
Natural  
Synthetic

## **CHAPTER 5 MARKET BREAKDOWN BY END USER**

Biopharmaceutical Companies  
Contract Research Organizations (CROs)  
Academic and Research Institutes  
Forensic Science Laboratories  
Food and Beverage Companies  
Application of Cell Lines and Cell Cultures  
The Benefits of Using Plant Cell Lines:  
Microbes for Food and Beverage Production  
Cell Lines in Clean Meat  
Diagnostic Centers  
Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research in Diagnostic Centers  
Cell Membrane Proteomics Can Potentially Identify Breast Cancer  
Others

## **CHAPTER 6 MARKET BREAKDOWN BY APPLICATION**

Drug Discovery and Development  
Application of Cell Line and Membrane in Drug Discovery and Development Process  
Surging Utilization of Cell Lines in Cancer Pharmacogenomics  
Clinical Trials  
Basic Research  
Benefits of Cell Line in Research  
Toxicity Screening  
Biopharmaceutical Production

The Use of Human Cell Line for Biopharmaceutical Production

The Use of CHO Cells for Biopharmaceutical Production

Driver

Drug Screening

Driver

Forensic Testing

Cell Line Authentication

Tissue Engineering

Stem Cell Applications in Tissue Engineering

Driver

## **CHAPTER 7 MARKET BREAKDOWN BY REGION**

North America

U.S.

Canada

Europe

U.K.

Germany

France

Spain

Rest of Europe

Asia-Pacific

China

India

Japan

Australia

ROAPAC

RoW (Rest of the World)

Latin America

Middle East and Africa

## **CHAPTER 8 CELL LINE AND MEMBRANE MARKET INDUSTRY STRUCTURE**

Procurement of Raw Materials

Quality

Terms and Conditions

Cost Effective Components

Manufacturing/Development Process

End Users

Factors Affecting Cell Line and Membrane Market

Innovation within the Industry

Various Gene Engineering Approaches

Advancements in Cell Lines for Cancer-Based Therapies

CAR T-Cell Lines and Immune Checkpoint Inhibitors

Autologous vs. Allogenic Cells Manufacturing Process

Competitive Analysis

## **CHAPTER 9 COMPANY PROFILES**

ABZENA

ACM BIOLABS

ATCC

BD BIOSCIENCES

BIOIVT

CATALENT INC.

CELL BIOLABS INC.

CORNING INC.

CREATIVE BIOLABS

ETUBICS CORP.

GE HEALTHCARE

IXCELLS BIOTECHNOLOGIES

LONZA GROUP LTD.

MI BIORESEARCH INC.

MERCK MILLIPORE

MILTENYI BIOTEC

NOVUS BIOLOGICALS

ROCKLAND IMMUNOCHEMICALS INC.

QUIDEL CORP.

SARTORIUS

SELEXIS SA

THERMO FISHER SCIENTIFIC

WUXI APPTec

## List Of Tables

### LIST OF TABLES

Summary Table: Global Market for Cell Line and Membrane, by Product, Through 2023

Table 1: Investment Analysis

Table 2: Investments in Cell Culture Technology

Table 3: Regional Analysis of Studies on Antibodies

Table 4: Total Global Pharmaceutical R&D Spending, 2015-2022

Table 5: Global Cell Line and Membrane Market, by Product, Through 2023

Table 6: Key Sources and Description of Biological Contamination of Cell Lines and Membranes

Table 7: Some Key Mammalian and Insect Cell Cultures

Table 8: List of Animal Cell Lines Used in Research

Table 9: Global Cell Line Market, by Type, Through 2023

Table 10: Global Cell Line Market, by Region, Through 2023

Table 11: NCI-60 Cancer Cell Lines

Table 12: Most Common Cancers, by Type, 2018

Table 13: Research Grants, by Cancer Type, August 2018

Table 14: Global Cell Membrane Market, by Type, Through 2023

Table 15: Global Pharmaceutical R&D Spending, 2015-2022

Table 16: Global Cell Membrane Market, by Region, Through 2023

Table 17: Global Cell Line and Membrane Market, by End User, Through 2023

Table 18: Global Biopharmaceutical Companies Market, by Region, Through 2023

Table 19: Cell Lines Used in the Production of Biopharmaceuticals

Table 20: Global Growth in Pharmaceutical Market, 2015 and 2020

Table 21: Global Biologics Spending, 2011 and 2016

Table 22: Global Biosimilars Spending, 2011 and 2016

Table 23: Global Contract Research Organizations (CROs) Market, by Region, Through 2023

Table 24: Drug Development, by CRO, 2017 and 2018

Table 25: Global Academic and Research Institutes Market, by Region, Through 2023

Table 26: Cell Lines Research and Development in Academic and Research Institutes, 2017 and 2018

Table 27: Global Prevalence of Dementia, 2015-2050

Table 28: Global Forensic Science Laboratories Market, by Region, Through 2023

Table 29: Global Food and Beverage Companies Market, by Region, Through 2023

Table 30: Microbial Strains Used in Food and Beverage Industries

Table 31: Global Diagnostic Centers Market, by Region, Through 2023

- Table 32: Global Other End Users Market, by Region, Through 2023
- Table 33: Global Cell Line and Membrane Market, by Application, Through 2023
- Table 34: Global Drug Discovery and Development Market, by Region, Through 2023
- Table 35: International Cancer Research Projects Share, by Region, 2017-2018
- Table 36: American Chemical Society Grants, by Cancer Type, 2018
- Table 37: Investment in Cancer Research in Canada, by Cancer Type, 2016
- Table 38: Drugs in Development, by Disease Type, 2017
- Table 39: Pharmaceutical Spending, by Country, 2016
- Table 40: Global Basic Research Market, by Region, Through 2023
- Table 41: U.S. R&D Funding Share, 2016
- Table 42: Global Toxicity Screening Market, by Region, Through 2023
- Table 43: Member Companies of the Pharmaceutical Research and Manufacturers of America R&D Investments (U.S.), 2005-2016
- Table 44: Investments in Personalized Medicine, 2017 and 2018
- Table 45: Global Biopharmaceutical Production Market, by Region, Through 2023
- Table 46: U.S. Food and Drug Administration-Approved Protein Therapeutics, 2015-2016
- Table 47: Comparison of Human Cell Lines with Other Expression Systems in the Production of Therapeutic Proteins
- Table 48: Monoclonal Antibodies Approved by the European Medical Agency and Food and Drug Administration for Therapeutic Use Status, 2015-2017
- Table 49: Pharmaceutical R&D Expenditure in Europe, the U.S. and Japan, 2010 and 2015
- Table 50: Global Drug Screening Market, by Region, Through 2023
- Table 51: Advantages and Disadvantages of the Use of Cancer Cell Lines as Models in Cancer Research
- Table 52: Estimated New Cases of Leukemia, Lymphoma, and Myeloma, 2018
- Table 53: Global Forensic Testing Market, by Region, Through 2023
- Table 54: Current Status of SNP, STR, and DNA Barcode Technologies as Standard Methods for Assessing the Identity of Cell Lines from Different Species
- Table 55: Global Tissue Engineering Market, by Region, Through 2023
- Table 56: NIH Spending Trend on Stem Cell Research, 2015-2018
- Table 57: Global Cell Line and Membrane Market, by Region, Through 2023
- Table 58: North American Cell Line and Membrane Market, by Country, Through 2023
- Table 59: NIH Spending on Stem Cell Research, 2013-2016
- Table 60: North American Cell Line and Membrane Market, by Product, Through 2023
- Table 61: NIH Funding for CRISPR-Related Research, 2006-2016
- Table 62: North American Cell Line and Membrane Market, by End User, Through 2023
- Table 63: Net Spending on Biologics in the U.S., 2013-2017



Table 64: North American Cell Line and Membrane Market, by Application, Through 2023

Table 65: Percentage Increase of Spending on Biologics in Canada, 2011-2016

Table 66: European Cell Line and Membrane Market, by Country, Through 2023

Table 67: Pharmaceutical Industry R&D Expenditures in Selected European Countries

Table 68: Cumulative Spending on Biosimilar Medicines in the EU5, 2016-2020

Table 69: European Cell Line and Membrane Market, by Product, Through 2023

Table 70: U.K. Pharmaceutical R&D Expenditures, 2014 and 2015

Table 71: European Cell Line and Membrane Market, by End User, Through 2023

Table 72: European Cell Line and Membrane Market, by Application, Through 2023

Table 73: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2016

Table 74: Asia-Pacific Cell Line and Membrane Market, by Country, Through 2023

Table 75: Asia-Pacific Cell Line and Membrane Market, by Product, Through 2023

Table 76: Studies Recruiting Under Phase IV, Based on Cell Line

Table 77: Number of People with Cancer in China, 2010-2016

Table 78: Asia-Pacific Cell Line and Membrane Market, by Application, Through 2023

Table 79: Growth in Biotech Industry in India, 2010-2017

Table 80: Some of the Approved Biosimilar Products in India

Table 81: Growing Number of Cancer Patients in India, 2010-2016

Table 82: Asia-Pacific Cell Line and Membrane Market, by End User, Through 2023

Table 83: R&D Spending in India, by Top Pharmaceutical Companies, 2016

Table 84: List of Biotech Companies Supported by Osaka University in Cell Culture

Table 85: Estimated Most Common Cancer Diagnosed, by Type, 2018

Table 86: Commonly Diagnosed Cancers in Australia, 2017

Table 87: Rest of the World Cell Line and Membrane Market, by Country, Through 2023

Table 88: Rest of the World Cell Line and Membrane Market, by Product, Through 2023

Table 89: Rest of the World Cell Line and Membrane Market, by End User, Through 2023

Table 90: Rest of the World Cell Line and Membrane Market, by Application, Through 2023

Table 91: Global Suppliers to Cell Line and Membrane Market

Table 92: Some of the Major Cell Line and Membrane Companies

Table 93: FDA Center for Drug Evaluation and Research Approved Biologics Based on Cell Lines, 2015

Table 94: Some CRISPR-Cas-Based Gene Editing Techniques Used for Manipulation of Various Organisms

Table 95: CAR T-Cell Therapy in Immuno-Oncology Medicine Development, 2017

Table 96: Global CAR T-Cell Therapy Market, by Region, Through 2023

Table 97: Global Immune Checkpoint Inhibitor Therapy Market, by Region, Through 2023

Table 98: FDA-Approved Immune Checkpoint Inhibitors

Table 99: Global Distribution of All Studies on Immune Checkpoint Inhibitors, by Region/Country

Table 100: Autologous vs. Allogenic Cells Manufacturing Process

Table 101: Abzena: Product Portfolio

Table 102: Abzena: Recent Developments

Table 103: ACM Biolabs: Product Portfolio

Table 104: ACM Biolabs: Recent Developments, January 2018 to December 2018

Table 105: ATCC: Product Portfolio

Table 106: ATCC: Recent Developments, 2015 to September 2018

Table 107: BD Biosciences: Product Portfolio

Table 108: BioIVT: Product Portfolio

Table 109: BioIVT: Recent Developments, 2015 to September 2018

Table 110: Catalent Inc.: Product Portfolio

Table 111: Catalent Inc.: Recent Developments, 2015 to September 2018

Table 112: Cell Biolabs Inc.: Product Portfolio

Table 113: Corning Inc.: Product Portfolio

Table 114: Creative Biolabs: Product Portfolio

Table 115: Etubics Corp.: Product Portfolio

Table 116: Etubics Corp.: Recent Developments, 2015 to September 2018

Table 117: GE Healthcare: Product Portfolio

Table 118: GE Healthcare: Recent Developments, 2015 to September 2018

Table 119: iXCells Biotechnologies: Product Portfolio

Table 120: Lonza Group Ltd.: Product Portfolio

Table 121: Lonza Group Ltd.: Recent Developments, 2015 to September 2018

Table 122: MI Bioresearch Inc.: Product Portfolio

Table 123: Merck Millipore: Product Portfolio

Table 124: Merck Millipore: Recent Developments, 2015 to September 2018

Table 125: Miltenyi Biotec: Product Portfolio

Table 126: Miltenyi Biotec: Recent Developments, 2015 to September 2018

Table 127: Novus Biologicals: Product Portfolio

Table 128: Novus Biologicals: Recent Developments, 2015 to September 2018

Table 129: Rockland Immunochemicals Inc.: Product Portfolio

Table 130: Rockland Immunochemicals Inc.: Recent Developments, 2015 to September 2018

Table 131: Quidel Corp.: Product Portfolio

Table 132: Quidel Corp.: Recent Developments, 2015 to September 2018

Table 133: Sartorius: Product Portfolio

Table 134: Selexis SA: Product Portfolio

Table 135: Thermo Fisher Scientific: Product Portfolio

Table 136: Thermo Fisher Scientific: Recent Developments, 2015 to September 2018

Table 137: WuXi AppTec: Product Portfolio

Table 138: WuXi AppTec: Recent Developments, 2015 to June 2018

## List Of Figures

### LIST OF FIGURES

Summary Figure: Global Market for Cell Line and Membrane, by Product, 2017-2023

Figure 1: Types of Cell Line Technologies

Figure 2: Total Global Pharmaceutical R&D Spending, 2015-2022

Figure 3: PhRMA Member Company R&D Expenditures, 2010 and 2016

Figure 4: Process of Deriving a Cell Line

Figure 5: Type of Cell Lines

Figure 6: Process of Growing Cell Lines and Delivering to Patients

Figure 7: Production Process of Ion Channel Cell Line

Figure 8: GPCR Cell Line Development Process

Figure 9: Applications of Cell Signaling Pathway Cell Lines

Figure 10: Generation of Knockout Cell Lines

Figure 11: Most Common Cancers, by Type, 2018

Figure 12: Production Process of Monoclonal Antibodies from Hybridoma Cell Lines

Figure 13: Global Pharmaceutical R&D Spending, 2015-2022

Figure 14: Common Benefits of Human Cell Lines in the Production of Therapeutic Proteins

Figure 15: Biopharmaceutical Production Using Mammalian Cells

Figure 16: Global Growth in Pharmaceutical Market, 2015 and 2020

Figure 17: Global Biologics Spending, 2011 and 2016

Figure 18: Global Biosimilars Spending, 2011 and 2016

Figure 19: Cell Lines and Membranes Application in Academic and Research Institutes

Figure 20: Global Prevalence of Dementia, 2015-2050

Figure 21: Advantages of Short Tandem Repeat Profiling in Cell Line Authentication

Figure 22: Workflow for Authentication of Cell Lines

Figure 23: Clean Meat Development Process Through Cell Lines

Figure 24: Meat Consumption, 2015-2027

Figure 25: Workflow Outlines Process of Obtaining Plasma Membrane Proteome of Multiple BC Cell Lines

Figure 26: Storage of Cell Lines in Cell Bank

Figure 27: Major Factors Driving the Growth of the Cell Line and Membrane Market, by Application

Figure 28: International Cancer Research Projects Share, by Region, 2017-2018

Figure 29: Drugs Share in Development, by Disease Type, 2017

Figure 30: Pharmaceutical Spending, by Country, 2016

Figure 31: U.S. R&D Funding Share, 2016

Figure 32: Member Company of Pharmaceutical Research and Manufacturers of America R&D Investment (U.S.), 2005-2016

Figure 33: Pharmaceutical R&D Expenditure in Europe, U.S. and Japan, 2010 and 2015

Figure 34: STR Analysis of Cell Lines

Figure 35: The Basic Materials and Processes Needed for Tissue Engineering Technologies

Figure 36: NIH Spending Trend on Stem Cell Research, 2015-2018

Figure 37: NIH Spending on Stem Cell Research, 2013-2016

Figure 38: Net Spending on Biologics in the U.S., 2013-2017

Figure 39: Pharmaceutical Industry R&D Expenditure in Selected European Countries

Figure 40: U.K. Pharmaceutical R&D Expenditures, 2014 and 2015

Figure 41: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2016

Figure 42: Number of People with Cancer in China, 2010-2016

Figure 43: Growth in Biotech Industry in India, 2010-2017

Figure 44: Growing Number of Cancer Patients in India, 2010-2016

Figure 45: R&D Spending in India, by Top Pharmaceutical Companies, 2016

Figure 46: Japan Pharmaceuticals Industry, 2010-2015

Figure 47: Estimated Most Common Cancer Diagnosed, by Type, 2018

Figure 48: Industry Structure of the Cell Line and Membrane Market

Figure 49: Cell Line Development Flow chart

Figure 50: CAR T-Cell Therapy Mechanism

Figure 51: Global CAR T-Cell Therapy Market, by Region, 2017-2023

Figure 52: Global Immune Checkpoint Inhibitor Therapy Market, by Region, 2017-2023

Figure 53: Global Distribution of All Studies on Immune Checkpoint Inhibitors, by Region/Country

Figure 54: Competitive Analysis Share for Cell Line and Membrane Market, by Strategies

## I would like to order

Product name: Cell Line and Membrane Market

Product link: <https://marketpublishers.com/r/C69CC3205C1EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C69CC3205C1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970